ClinicalTrials.gg
RecruitingNCT05457595CYCLOPSUpdated Aug 6, 2025

Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies

An interventional study of carbon ion radiation therapy in Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva and Malignant Epithelial Tumor of Ovary, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Feb 2021, registered Jul 2022).
  • Started Feb 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The study aims to obtain a local control rate in patients with lateral pelvic relapses of gynecologycal cancers previously irradiated. High LET (Linear Energy Transfer) particles as carbon ions can guarantee a biologic advantage compared to photons in radioresistant neoplasms, given to their higher biological efficacy (RBE).

Read the detailed description

Primary aim: estimate the effect, in terms of clinical response, of carbon ion treatment (CIRT) in patients with lateral pelvic recurrences of gynecological malignancies.

Secondary aims:

  1. To describe the safety profile of carbon ion therapy.
  2. To estimate the effect, in terms of survival, of carbon ion treatment
02

Conditions studied

  • Tumor Recurrence
  • Malignant Epithelial Neoplasm of Vulva
  • Malignant Epithelial Tumor of Ovary
  • Malignant Epithelial Neoplasm

Browse trials for

Keywords

  • gynecological cancer
  • carbon ion radiation therapy
  • recurrencies
  • CIRT
03

In context

Lead sponsor

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age
  • Index ≥ 70
  • Histological or radiological diagnosis of pelvic and groin recurrence
  • for radical surgery
  • No other distant progression or stable disease (SD) of known secondarisms (≥6 months)
  • Previous radiation therapy on pelvis
  • Distance ≥ 10mm between tumour and close intestinal tract (small intestine), radiologically evaluated
  • Possibility to perform a surgery to space the intestinal loops, in case of distance \< 10mm
  • If needed, spacer in biocompatible material (silicon, goretex) or anatomical material (omentum, muscle patch), non-absorbable.
  • DICOM (Digital Imaging and COmmunications in Medicine) images of the previous treatment plan availability
  • Written
  • Patient's ability to understand the characteristics and consequences of the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Hip prosthesis, metal prostheses or any other condition that prevents adequate imaging to identify the target volume and calculate the dose in the treatment plan

    • Intestinal infiltration
    • Bladder infiltration
    • Vessel infiltration
    • Previous therapy with anti-angiogenesis drugs
    • Psychic or other disorders that may prevent
    • Previous invasive tumor, with the exception of skin cancer (excluding melanoma) unless disease-free for at least 3 years
    • Spacer in absorbable material (i.e. vycril)
    • Distance \< 10mm between tumour and close intestinal tract (small intestine), radiologically evaluated
    • Impossibility to assess MRI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    carbon ion radiotherapy

    All enrolled subjects will undergo carbon ion radiation therapy. Patients affected by pelvic recurrence of gynecological neoplasia, already undergone to radiotherapy on pelvis, will be enrolled in the study.

    Radiation: carbon ion radiation therapy

Interventions

  • Radiationcarbon ion radiation therapy

    CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks. Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted.

    Also known as: CIRT

06

What researchers measure

Primary outcomes

  1. local control

    absence of progression disease, in patients with lateral pelvic recurrences of gynecological malignancies

    Time frame: 1 year after treatment

  2. complete response

    complete regression of the tumor lesion

    Time frame: 1 year after treatment

  3. partial response

    Reduction of the tumor volume \> 65% of the initial volume

    Time frame: 1 year after treatment

  4. stable disease

    Volume between PR and PD

    Time frame: 1 year after treatment

  5. progression disease

    Volume increase \> 73% of the initial volume.

    Time frame: 1 year after treatment

Secondary outcomes

  1. overall survival

    overall survival

    Time frame: 1 year after treatment

  2. Toxicity assessment according to CTCAE v. 5

    Tto define acute, intermediate and late toxicities according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)

    Time frame: 1 year after treatment

  3. Progression free survival

    Progression free survival (PFS) with qualitative evaluation as a narrative of progression

    Time frame: 1 year after treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Feb 2028, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2022
First posted
Jul 14, 2022
StartActual
Feb 24, 2021
Primary completionEst.
Feb 24, 2028
CompletionEst.
Feb 25, 2028
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05457595
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Feb 24, 2021
Primary completion
Feb 24, 2028 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Aug 6, 2025

Study contacts

Amelia Barcellini, MD
Contact
amelia.barcellini@cnao.it
390382075501
Cristina Bono, MSc
Contact
cristina.bono@cnao.it
390382075613
Amelia Barcellini, MD
principal investigator · CNAO National Center of Oncological Hadrontherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion